Alcon (ALC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Shares of Nevro Corp. (NYSE:NVRO – Get Free Report) have earned a consensus rating of “Reduce” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. Two investment ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Corp (NVRO – Research Report), Globus ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring ...

Stifel重申买入评级和94.00美元的目标价，反映了对Globus Medical并购后指引和预期财务表现的审慎评估。该分析为投资者提供了一个框架，用于衡量这家医疗器械公司在未来几年实现每股收益增长目标所需的努力。凭借2.54的健康流动比率和适度的债务水平，GMED似乎已做好执行并购战略的准备。

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Nevro Corp是一家全球医疗器械公司，专注于提供继续为慢性疼痛治疗持久患者结果设定标准的全面的、改变生活的解决方案。该公司开发并商业化Senza脊髓刺激（SCS）系统。SCS是一个用于治疗慢性疼痛的神经调节平台，除了Senza系列产品之外，还包括Senza Omnia平台。